CurrentCignaPolicy N/A

Anticoagulants - Savaysa Prior Authorization Policy

This policy governs prior authorization requirements for Savaysa (edoxaban) for prescription benefit plans administered by Cigna companies and applies to prescribing providers and pharmacists managing coverage determinations.

Policy Summary

PayerCigna

PolicyAnticoagulants - Savaysa Prior Authorization Policy

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateMay 21, 2025

Key ActionSubmit prior authorization requests with supporting clinical documentation; approvals are provided for specified durations (e.g., 1 year for atrial fibrillation and DVT/PE).

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

FDA‑approvedIndications covered

Avoid if CrCl >95Boxed warning / limitation

60 days–1 yrAuth lengths

≥18 yrsMin patient age

Prior auth recommendedAuthorization stance

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Atrial Fibrillation (or Atrial Flutter)

Approve for 1 year if BOTH of the following are met

Atrial Fibrillation criteria: A) Patient is >= 18 years of age; AND B) Patient has an estimated creatinine clearance <= 95 mL/min.

Approval duration: 1 year

Deep Vein Thrombosis or Pulmonary Embolism, Treatment

Approve for 1 year if the following is met

DVT/PE treatment criteria: Patient is >= 18 years of age.

Approval duration: 1 year

Other Uses with Supportive Evidence

Approve when criteria below are met

VTE prophylaxis after hip replacement: Patient is >= 18 years of age.

Approval duration: 60 days

Other thromboembolic-related conditions: A) Patient is >= 18 years of age; AND B) Patient meets ONE of: (i) tried warfarin, fondaparinux, or a low molecular weight heparin product; OR (ii) patient has been started on Savaysa for treatment of an acute thromboembolic condition.

Approval duration: 6 months

Any use of Savaysa (edoxaban) that is not specifically described as covered in this policy is considered not medically necessary. The policy explicitly lists that Savaysa is not medically necessary for any other use(s) not covered in the criteria section and provides examples to illustrate this exclusion.

One specific example noted in the policy is venous thromboembolism (VTE) prophylaxis in an acutely ill medical patient, which is listed under the conditions considered not medically necessary.

As a general fallback, if a requested use for Savaysa is not described among the covered indications and corresponding criteria in this policy, the request should be denied as not medically necessary. Providers should refer to the policy’s covered indications and supporting criteria when submitting prior authorization requests.

The policy provides an explicit example to guide determinations: prophylaxis of venous thromboembolism in an acutely ill medical patient is listed as a use that is not medically necessary for Savaysa.

Coding and Clinical Thresholds

Covered / referenced coding guidancemixed

No codes listed

Creatinine clearance threshold — AF indication

Creatinine clearance thresholdEstimated creatinine clearance ≤ 95 mL/min is required for the atrial fibrillation indication (avoid use if > 95 mL/min)

ApplicabilityThis threshold applies specifically to the non‑valvular atrial fibrillation (or atrial flutter) indication

Source guidanceSavaysa has a boxed warning: reduced efficacy in patients with creatinine clearance > 95 mL/min; should be avoided

Minimum age

Minimum age requirementPatient must be ≥ 18 years of age for covered indications

Indications noting ageApplies to atrial fibrillation, DVT/PE treatment, hip replacement prophylaxis, and other thromboembolic‑related conditions

Pediatric statementSafety and effectiveness in pediatric patients have not been established

Provider Actions, Documentation, and Authorization

Prior Authorization

Prior Authorization Recommended

Prior Authorization is recommended for prescription benefit coverage of Savaysa. Approvals are provided for the durations aligned with the indication (e.g., 1 year for atrial fibrillation and DVT/PE, 60 days for hip replacement prophylaxis, 6 months for other thromboembolic-related conditions). Submit prior authorization requests per the member's benefit plan.

Savaysa approvals: AF — 1 year; DVT/PE (treatment) — 1 year; DVT prophylaxis after hip replacement — 60 days; Other thromboembolic-related conditions — 6 months.

Documentation Required

Required Supporting Documentation

Providers must submit supporting clinical documentation with prior authorization or coverage requests. Documentation should demonstrate the FDA‑approved indication or supportive evidence for other uses, patient age, and relevant renal function (e.g., estimated creatinine clearance when applicable). For thromboembolic conditions, include clinical notes, diagnostic test results, and treatment history that justify the requested duration.

Include patient age and estimated creatinine clearance for atrial fibrillation requests (must be ≤ 95 mL/min).
Provide documentation of diagnosis (e.g., imaging for DVT/PE) and treatment plan for DVT/PE and prophylaxis requests.

Step Therapy

Step/Therapy Requirement

For certain thromboembolic-related conditions (other than AF or DVT/PE treatment), a trial of warfarin, fondaparinux, or a low molecular weight heparin (e.g., enoxaparin, dalteparin) is required unless the patient was initiated on Savaysa for acute treatment. Document prior anticoagulant trial(s) and reason for failure or intolerance, or document that Savaysa was started for acute treatment.

Step requirement applies to "other thromboembolic-related conditions" approved for 6 months.
Prior trial of warfarin, fondaparinux, or LMWH must be documented OR documentation that Savaysa was started for acute thromboembolic treatment.

Denial Risk

Denial Triggers

Claims submitted without covered diagnosis or procedure codes consistent with the policy will be denied. Savaysa is subject to the coverage criteria above; requests or claims that do not meet these criteria or lack required documentation may be denied.

Ensure billing uses appropriate covered diagnosis/procedure codes per the benefit plan.
Incomplete clinical documentation or lack of required prior trials may trigger denial.

Background

Edoxaban (Savaysa) is an oral direct Factor Xa inhibitor approved to reduce the risk of stroke and systemic embolism in non‑valvular atrial fibrillation and for the treatment of deep vein thrombosis and pulmonary embolism following initial parenteral anticoagulation. Clinical guidelines generally prefer direct oral anticoagulants (DOACs) like edoxaban over warfarin for eligible patients.

The prescribing information includes an important safety consideration: an estimated creatinine clearance > 95 mL/min is associated with reduced efficacy of edoxaban and the drug should be avoided in such patients. The policy applies these clinical parameters in its coverage criteria, including a minimum age requirement of ≥ 18 years for covered uses.

Definitions and Key Safety Notes

DOAC — Direct oral anticoagulant (definition)

DefinitionDOAC = Direct oral anticoagulant; oral agents (including edoxaban/Savaysa) that directly inhibit coagulation factors and are commonly used for DVT/PE and atrial fibrillation

Clinical preferenceGuidelines generally prefer DOACs over vitamin K antagonists (e.g., warfarin) for eligible patients

Examples (context)Edoxaban (Savaysa) is a Factor Xa inhibitor categorized as a DOAC

CrCl > 95 mL/min (boxed warning)

Boxed warning summaryEstimated creatinine clearance > 95 mL/min is associated with reduced efficacy of Savaysa; avoid use in these patients

Clinical implicationDo not initiate Savaysa for atrial fibrillation in patients with CrCl > 95 mL/min due to reduced efficacy

Related approval criteriaAtrial fibrillation approval requires estimated CrCl ≤ 95 mL/min

OpenPayer

Anticoagulants - Savaysa Prior Authorization Policy

Coverage Criteria for Savaysa (edoxaban)

Coding and Clinical Thresholds

Provider Actions, Documentation, and Authorization

Background

Definitions and Key Safety Notes